Gender Disparities and Associated Factors to Intention to Getting a Second Dose of COVID-19 AstraZeneca Vaccine Among Adult Populations in Selected Facilities of Lusaka, Zambia

Overview

Journal PLOS Glob Public Health

Specialty Public Health

Date 2023 Mar 24

PMID 36962377

Authors

Choolwe Jacobs

Nedah Chikonde Musonda

Deborah Tembo

Miyanda Simwaka

Evelyn Mwamba

Sody Mweetwa Munsaka

Samson Shumba

Affiliations

Soon will be listed here.

Abstract

As COVID-19 vaccines are becoming more available, there is also a growing need to understand the population receiving the doses, existing inequalities and the intention to getting the second vaccine dose among the populations that receive the vaccines. We evaluated gender inequalities and intention to uptake of the second dose of COVID-19 AstraZeneca vaccine among adult populations in selected urban facilities of Lusaka, Zambia. A cross-sectional study design was conducted between May and June 2021 among adults who received AstraZeneca vaccine from three selected urban facilities of Lusaka, Zambia. Phone-based interviews were conducted 6 weeks after the first dose of the vaccine. Descriptive analysis and mixed-effect logistic regression were done using STATA version 16.2. Of the 1321 adults who had received AstraZeneca vaccine, 868 respondents completed the questionnaire. About, 47% (408/868) were females and 53% (460/868) were males. Median age in the study was 40 years. Majority of males were educated (54%) and employed (57%). Furthermore, majority of females that got the first dose of AstraZeneca reported experiencing side effects (76.98%) compared to males (64.24%). Among study participants, 93.7% intended to receive the AstraZeneca vaccine, of whom 46.7% (380/814) were females and 52.9% (434/814) were males. Majority of participants that did not intend to get a second dose were not married (55.56%). Only age (AOR, 1.05; 95% CI, 1.02-1.08) predicted intention to getting a second dose of AstraZeneca vaccine. We found important gender-dependent differences in the side effects reported by females that received the first dose of Astra Zeneca. Finding that intention to get the second dose of the vaccine increased with age suggests a need for enhancing COVID-19 vaccination programmes targeting young people and a need for further research to identify specific adverse effects of COVID-19 Astra Zeneca vaccines.

Citing Articles

Determinants of COVID-19 vaccine acceptance and hesitancy among adolescents and youths aged 10-35 years in sub-Saharan African countries: A systematic review and meta-analysis.

Mwiinde A, Kaonga P, Jacobs C, Zulu J, Fwemba I PLoS One. 2024; 19(10):e0310827.

PMID: 39374213 PMC: 11458002. DOI: 10.1371/journal.pone.0310827.

Predicting Mortality in Hospitalized COVID-19 Patients in Zambia: An Application of Machine Learning.

Mulenga C, Kaonga P, Hamoonga R, Mazaba M, Chabala F, Musonda P Glob Health Epidemiol Genom. 2023; 2023:8921220.

PMID: 37260675 PMC: 10228226. DOI: 10.1155/2023/8921220.

References

Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P . Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infect Dis. 2021; 21(7):939-949. PMC: 8078878. DOI: 10.1016/S1473-3099(21)00224-3. View

Carcelen A, Prosperi C, Mutembo S, Chongwe G, Mwansa F, Ndubani P . COVID-19 vaccine hesitancy in Zambia: a glimpse at the possible challenges ahead for COVID-19 vaccination rollout in sub-Saharan Africa. Hum Vaccin Immunother. 2021; 18(1):1-6. PMC: 8920139. DOI: 10.1080/21645515.2021.1948784. View

Mathew N, Deborah I, Karonga T, Rumbidzai C . The impact of COVID-19 lockdown in a developing country: narratives of self-employed women in Ndola, Zambia. Health Care Women Int. 2020; 41(11-12):1370-1383. DOI: 10.1080/07399332.2020.1823983. View

Sallam M . COVID-19 Vaccine Hesitancy Worldwide: A Concise Systematic Review of Vaccine Acceptance Rates. Vaccines (Basel). 2021; 9(2). PMC: 7920465. DOI: 10.3390/vaccines9020160. View

Alqudeimat Y, Alenezi D, Alhajri B, Alfouzan H, Almokhaizeem Z, Altamimi S . Acceptance of a COVID-19 Vaccine and Its Related Determinants among the General Adult Population in Kuwait. Med Princ Pract. 2021; 30(3):262-271. PMC: 8089409. DOI: 10.1159/000514636. View

Fontanet A, Cauchemez S . COVID-19 herd immunity: where are we?. Nat Rev Immunol. 2020; 20(10):583-584. PMC: 7480627. DOI: 10.1038/s41577-020-00451-5. View

Jahan N, Rahman F, Saha P, Ether S, Roknuzzaman A, Sarker R . Side Effects Following Administration of the First Dose of Oxford-AstraZeneca's Covishield Vaccine in Bangladesh: A Cross-Sectional Study. Infect Dis Rep. 2021; 13(4):888-901. PMC: 8544399. DOI: 10.3390/idr13040080. View

Du Toit A . Outbreak of a novel coronavirus. Nat Rev Microbiol. 2020; 18(3):123. PMC: 7073251. DOI: 10.1038/s41579-020-0332-0. View

Kiely M, Boulianne N, Talbot D, Ouakki M, Guay M, Landry M . Impact of vaccine delays at the 2, 4, 6 and 12 month visits on incomplete vaccination status by 24 months of age in Quebec, Canada. BMC Public Health. 2018; 18(1):1364. PMC: 6288945. DOI: 10.1186/s12889-018-6235-6. View

10.

Robertson E, Reeve K, Niedzwiedz C, Moore J, Blake M, Green M . Predictors of COVID-19 vaccine hesitancy in the UK household longitudinal study. Brain Behav Immun. 2021; 94:41-50. PMC: 7946541. DOI: 10.1016/j.bbi.2021.03.008. View

11.

Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P . Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020; 397(10269):99-111. PMC: 7723445. DOI: 10.1016/S0140-6736(20)32661-1. View

12.

Jain R, Chopra A, Falezan C, Patel M, Dupas P . COVID-19 related immunization disruptions in Rajasthan, India: A retrospective observational study. Vaccine. 2021; 39(31):4343-4350. PMC: 8196298. DOI: 10.1016/j.vaccine.2021.06.022. View

13.

Solis Arce J, Warren S, Meriggi N, Scacco A, McMurry N, Voors M . COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries. Nat Med. 2021; 27(8):1385-1394. PMC: 8363502. DOI: 10.1038/s41591-021-01454-y. View

14.

Schaffer DeRoo S, Pudalov N, Fu L . Planning for a COVID-19 Vaccination Program. JAMA. 2020; 323(24):2458-2459. DOI: 10.1001/jama.2020.8711. View

15.

Karlsson L, Soveri A, Lewandowsky S, Karlsson L, Karlsson H, Nolvi S . Fearing the disease or the vaccine: The case of COVID-19. Pers Individ Dif. 2021; 172:110590. PMC: 7832025. DOI: 10.1016/j.paid.2020.110590. View

16.

Yassin N, Saleh S . The World after COVID-19: Reflections on Global Health and Policy. Ann Glob Health. 2021; 87(1):72. PMC: 8300582. DOI: 10.5334/aogh.2902. View

17.

Parashar S . Moving beyond the mother-child dyad: women's education, child immunization, and the importance of context in rural India. Soc Sci Med. 2005; 61(5):989-1000. DOI: 10.1016/j.socscimed.2004.12.023. View

18.

MacDonald N . Vaccine hesitancy: Definition, scope and determinants. Vaccine. 2015; 33(34):4161-4. DOI: 10.1016/j.vaccine.2015.04.036. View

19.

Koirala A, Joo Y, Khatami A, Chiu C, Britton P . Vaccines for COVID-19: The current state of play. Paediatr Respir Rev. 2020; 35:43-49. PMC: 7301825. DOI: 10.1016/j.prrv.2020.06.010. View

20.

Painter E, Ussery E, Patel A, Hughes M, Zell E, Moulia D . Demographic Characteristics of Persons Vaccinated During the First Month of the COVID-19 Vaccination Program - United States, December 14, 2020-January 14, 2021. MMWR Morb Mortal Wkly Rep. 2021; 70(5):174-177. PMC: 7861480. DOI: 10.15585/mmwr.mm7005e1. View